97.00Open97.00Pre Close0 Volume0 Open Interest390.00Strike Price0.00Turnover95.78%IV-15.81%PremiumDec 20, 2024Expiry Date136.99Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9827Delta0.0015Gamma1.85Leverage Ratio-0.0429Theta-0.0527Rho-1.81Eff Leverage0.0227Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet